TR199802648A2 - Gen tedavisi için nüklein asit yapilari. - Google Patents

Gen tedavisi için nüklein asit yapilari.

Info

Publication number
TR199802648A2
TR199802648A2 TR1998/02648A TR9802648A TR199802648A2 TR 199802648 A2 TR199802648 A2 TR 199802648A2 TR 1998/02648 A TR1998/02648 A TR 1998/02648A TR 9802648 A TR9802648 A TR 9802648A TR 199802648 A2 TR199802648 A2 TR 199802648A2
Authority
TR
Turkey
Prior art keywords
gene therapy
nucleic acid
acid structures
nucleic acids
protein
Prior art date
Application number
TR1998/02648A
Other languages
English (en)
Other versions
TR199802648A3 (tr
Inventor
Eilers Martin
Buergin Andrea
Sedlacek Hans-Harald
Original Assignee
Hoechst Marion Roussel Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Deutschland Gmbh filed Critical Hoechst Marion Roussel Deutschland Gmbh
Publication of TR199802648A2 publication Critical patent/TR199802648A2/tr
Publication of TR199802648A3 publication Critical patent/TR199802648A3/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)

Abstract

Selüler protein p27'yi inhibe eden ve bu sayede p27 ile etkilenen hücre proliferasyonu önlenmesini ortadan kaldiran bir protein için kodlayan nükleinasitler içeren ve hastaliklarin gen tedavisi için nüklein asit yapilari, kismen egemen olarak etken karektere sahip mutantlar ve sözkonusu nüklein asitlerin hastaliklarin profilaksi ve tedavisi için sözkonusu nüklein asitlerin kullanimi ile ilgilidir.
TR1998/02648A 1997-12-20 1998-12-18 Gen tedavisi için nüklein asit yapilari. TR199802648A3 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19756975A DE19756975A1 (de) 1997-12-20 1997-12-20 Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung

Publications (2)

Publication Number Publication Date
TR199802648A2 true TR199802648A2 (tr) 1999-07-21
TR199802648A3 TR199802648A3 (tr) 1999-07-21

Family

ID=7852804

Family Applications (2)

Application Number Title Priority Date Filing Date
TR1998/02649A TR199802649A3 (tr) 1997-12-20 1998-12-18 Sikline bagli kinazlarin inhibitörleri için baglama esleri.
TR1998/02648A TR199802648A3 (tr) 1997-12-20 1998-12-18 Gen tedavisi için nüklein asit yapilari.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR1998/02649A TR199802649A3 (tr) 1997-12-20 1998-12-18 Sikline bagli kinazlarin inhibitörleri için baglama esleri.

Country Status (15)

Country Link
US (1) US6265562B1 (tr)
EP (2) EP0926237A3 (tr)
JP (2) JPH11313686A (tr)
KR (2) KR19990063284A (tr)
CN (2) CN1227871A (tr)
AR (2) AR016436A1 (tr)
AU (2) AU758030B2 (tr)
BR (2) BR9805151A (tr)
CA (2) CA2255141A1 (tr)
CZ (2) CZ422598A3 (tr)
DE (1) DE19756975A1 (tr)
HU (1) HUP9802961A3 (tr)
ID (2) ID21582A (tr)
PL (2) PL330452A1 (tr)
TR (2) TR199802649A3 (tr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
GB9727512D0 (en) * 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
AU2002365889A1 (en) * 2001-11-29 2003-06-17 Institutes For Pharmaceutical Discovery, Llc Regulated expression of recombinant dna
AU2006297112B2 (en) * 2005-10-01 2013-04-18 Charles Stout Regulatable fusion promoters
UA100692C2 (ru) 2007-05-02 2013-01-25 Мериал Лимитед Днк-плазмиды, имеющие повышенную экспрессию и стабильность
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US20210230221A1 (en) * 2017-01-03 2021-07-29 Bioatla, Llc Protein therapeutics for treatment of senescent cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
DE19605274A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme

Also Published As

Publication number Publication date
ID21582A (id) 1999-06-24
CN1227871A (zh) 1999-09-08
CA2255141A1 (en) 1999-06-20
US6265562B1 (en) 2001-07-24
TR199802649A2 (tr) 1999-07-21
AU9720498A (en) 1999-07-08
AR017887A1 (es) 2001-10-24
EP0926237A2 (de) 1999-06-30
HUP9802961A2 (hu) 1999-07-28
EP0926237A3 (de) 2000-01-05
JPH11308997A (ja) 1999-11-09
HU9802961D0 (en) 1999-02-01
AU758030B2 (en) 2003-03-13
CA2255143A1 (en) 1999-06-20
JPH11313686A (ja) 1999-11-16
AU747246B2 (en) 2002-05-09
BR9805151A (pt) 2000-03-21
KR19990063284A (ko) 1999-07-26
DE19756975A1 (de) 1999-06-24
CN1225367A (zh) 1999-08-11
AR016436A1 (es) 2001-07-04
BR9805152A (pt) 2000-03-21
TR199802649A3 (tr) 1999-07-21
KR19990063285A (ko) 1999-07-26
HUP9802961A3 (en) 2000-04-28
PL330451A1 (en) 1999-06-21
PL330452A1 (en) 1999-06-21
ID21534A (id) 1999-06-24
EP0926236A1 (de) 1999-06-30
CZ422598A3 (cs) 1999-07-14
CZ422398A3 (cs) 1999-07-14
TR199802648A3 (tr) 1999-07-21
AU9720598A (en) 1999-07-08

Similar Documents

Publication Publication Date Title
TR199802648A2 (tr) Gen tedavisi için nüklein asit yapilari.
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
ATE393831T1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
FI970768L (fi) Kasvainten geeniterapiahoito endoteelisoluspesifisellä, solusyklistä riippuvalla vaikuttavalla aineella
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
TR200102784T2 (tr) Diyabet tedavisi için ilaç
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
MX9800719A (es) Proteinas de transporte y sus usos.
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
NO864990D0 (no) Solubilisering av proteinaggregater.
BR9811956A (pt) Naftiridinonas para a inibição de proteìna tirosina cinase e de proliferação celular mediada por cinase de ciclo de célula
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
TR199901949T2 (tr) Lemfositik tümörler için çareler.
ATE293700T1 (de) Adenovirus mit glutathion peroxydate gene
TR199801395A2 (tr) Genetik olarak degistirilmis hücreler ve bunlarin kullanimlari.
EP1053315A4 (en) HUMAN 'HAARLOS' GENE AND PROTEIN AND THEIR USE
BR9809284A (pt) Construto e processo para expressão de polinucleotìdeo em altos nìveis
BR9808221A (pt) Método de tratamento de tumor.
PT1002095E (pt) Estirpes melhoradas para expressao de proteinas
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
DK0843731T3 (da) Adenovirusvektorer til genterapi
ATE226087T1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
EP1163373A4 (en) ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION
ATE362535T1 (de) Mutiertes cyclin g1 protein